Keros Therapeutics Inc

KROSNASDAQ · USD
11.02USD-0.50 (-4.34%)
915

Keros Therapeutics Inc (KROS) Option Chain

As of October 5, 2026, Keros Therapeutics Inc is trading at $11.02, a -4.34% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 145.3%. IV Rank is 73%.

Read more

Tracking the KROS option chain helps you see every strike and expiry on Keros Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Keros Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of KROS options activity at a glance. Use our scanner to monitor the KROS option chain in real time and filter for the KROS options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For KROS stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the KROS option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where KROS stock options are being actively traded and where they are not.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Keros Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen KROS options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of KROS stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile78.97% Elevated
  • Market cap (M$)228
  • 52 weeks high-48.91%
  • 52 weeks low18.89%
  • Analyst recommendationBuy
    1.86
  • Target price$19.83
    79.95% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-04
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.70
  • EPS growth next 5 years—

As of October 5, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
0.06000.236.024.008.505.00-56.60—0.750.000.750099.94
5.41000.283.521.606.007.50-34.90—0.750.000.750094.59
32.66201.561.020.254.9010.00-13.19—0.300.000.3002767.34
67.291001.300.00—1.3012.50+8.51—2.951.481.470032.71
88.12102.450.00—2.4515.00+30.211.505.903.98-0.280011.88

As of October 5, 2026

Scan the full option chain in one place

Browse the full KROS option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial